# Pharma Mutual Funds Just Outperformed Markets in 2026 | Too Late to Invest? > Pharma and healthcare mutual funds have emerged as strong performers in 2026. But with valuations rising, is there still an opportunity for investors? Explore the sector's growth drivers, key risks and what to consider before investing. - **URL**: https://www.arihantplus.com/blogs/mutual-funds/pharma-mutual-funds-just-outperformed-markets-in-2026-too-late-to-invest - **Category**: Mutual Funds - **Author**: [Arihant Team](https://www.arihantplus.com/author/arihant-team) - **Published**: 2026-11-11 - **Updated**: 2026-11-12 - **Reading time**: 7 minutes read --- ## Key Takeaways * _Pharma and healthcare mutual funds have delivered around 19% returns in 2026 so far, outperforming other equity mutual fund categories._ * _Growing demand for medicines, upcoming drug patent expiries, generic semaglutide launches and opportunities in contract manufacturing are driving the sector's growth._ * _Despite strong growth prospects, pharma stocks are trading at higher valuations than their historical averages, making fresh investments more expensive._ * _Rising costs, pricing pressure in the US, government price controls and dependence on China for raw materials remain key risks for the sector._ * _Investors should avoid chasing recent returns and consider pharma funds as a smaller part of a diversified portfolio rather than making them their main investment._ ## Introduction In a year where the Nifty 50 has slipped into negative territory, one corner of the market has quietly posted nearly 20 percent gains. Pharma and healthcare mutual funds are up [**18 percent YTD**](https://morningstar.in/tools/mutual-fund-category-performance.aspx?utm%5Fsource=chatgpt.com), making them the single best performing equity fund category in 2026 ahead of every other sector, every market cap segment, and even international funds. ![Equity Category Performance Table.png](https://d1uenl0z1eg3km.cloudfront.net/Equity_Category_Performance_Table_7941e93be4.png) That kind of gap between pharma and the broader market does not happen often. When it does, it forces a set of questions. Should you chase the rally? Take profits off the table? Or sit tight and let the thesis play out? ## What's actually driving the Indian pharma rally? Five forces help explain why pharma has emerged as one of the strongest performers of 2026: * **Defensive rotation:** When the Nifty 50 turned negative, institutional money moved into sectors with stable, predictable earnings. Pharma fits that description. Domestic demand for medicines is largely inelastic, and the Nifty Pharma index has a beta of just 0.58 against the Nifty 50, meaning it moves significantly less than the broader market. That lower volatility drew institutional flows through a difficult year for equities. * **Global patent cliff:** Patents on drugs generating nearly $142 billion in annual sales globally are set to expire between 2026 and 2030\. Major expirations in cardiovascular, metabolic, oncology and autoimmune categories play directly to India's strength in cost efficient generic manufacturing. After accounting for price erosion, the global opportunity could exceed $30 to $40 billion, of which Indian companies are expected to capture $3 to $5 billion. * **Semaglutide:** When Novo Nordisk's patent expired in India on 20 March 2026, it triggered a launch wave unlike anything the market had seen. Over 50 generic brands from more than 40 manufacturers entered within months, with prices crashing 70 to 90 percent. India's GLP-1 market, currently estimated at INR 1,000 to INR 1,200 crore, is projected to reach INR 4,500 to INR 5,000 crore by 2030\. Dr Reddy's is already targeting 87 countries for generic semaglutide as global patents fall. * **Growing demand:** Indian Pharmaceutical Market has posted double digit monthly growth through most of 2026, led by chronic therapy segments like cardiac, anti diabetic and CNS drugs. CRISIL projects compared sector revenue growth of 11 to 13 percent in FY27, up from 8 percent the previous year, with domestic market growth of 9 to 11 percent. * **CDMO and China+1 opportunities:** Global pharmaceutical companies are increasingly looking to diversify manufacturing beyond China. Indian companies providing contract development and manufacturing services, or CDMO, stand to benefit as international drugmakers outsource more research and production. [**US BIOSECURE Act**](https://www.bakermckenzie.com/en/insight/publications/2026/01/united-states-the-biosecure-act-becomes-law) has added to the focus on biotechnology supply chains, although its restrictions are being implemented gradually. ## Is it too late to invest now? Nifty Pharma PE sits at 40 to 42 times, roughly 22% above its five year median of 33.29\. The Healthcare Index trades at 43.40 times, about 17% above its own median. Neither screams bubble, but both are comfortably in overvalued territory. That said, the opportunity has not passed. The patent cliff is a multi-year event running through 2030\. The GLP-1 market is in its early innings domestically. CDMO revenues are expected to grow from $3.5 billion to $22 to $25 billion by 2035 according to[ **Boston Consulting Group.**](https://www.bcg.com/publications/2025/india-unleashing-the-tiger-indian-crdmo-sector) But there is a difference between a growing industry and an attractive investment at current prices. For investors with a five-to-seven-year horizon and a high tolerance for risk, a staggered SIP or STP may be more suitable than investing a large lump sum at elevated valuations. ## Should one book profits or keep holding? If you bought twelve to eighteen months ago, the question is whether the reasons you invested have changed. India's domestic pharma market is projected to grow from $60 billion to $130 billion by 2030, revenue growth is accelerating, and the shift towards chronic therapies is structural. Where it gets trickier is portfolio balance. If pharma now exceeds 15 percent of your equity portfolio, trimming to 10 to 12 percent is smart risk management. Think of it as portfolio hygiene, not a call on fundamentals. Rebalance what has grown beyond your target weight and hold the rest. ## What are the risks of investing in Indian pharma? Despite strong returns in 2026, pharma funds come with risks that investors should understand. High valuations: Pharma stocks are trading at over 40 times their earnings, meaning investors are paying a premium for future growth. If companies fail to meet these expectations, stock prices could fall. The sector has struggled before, particularly during 2015-2020, when intense competition and falling drug prices in the US hurt Indian pharma companies. * **Pressure on profit margins:** Indian drugmakers are facing rising raw material and shipping costs. They are also losing revenue from high-margin drugs such as Revlimid, a cancer treatment whose generic versions previously generated substantial profits. According to [**CRISIL Ratings,**](https://www.crisilratings.com/en/home/newsroom/press-releases/2026/09/pharma-to-see-stronger-dose-of-revenue-growth-at-11-13-percent-this-fiscal.html) operating margins could decline by 1.5-2 percentage points in FY27. * **Uncertainty in the US market:** While generic medicines are currently exempt from certain US pharmaceutical import tariffs, the [**US government's proclamation**](https://thefederalregister.org/documents/2026-06956/adjusting-imports-of-pharmaceuticals-and-pharmaceutical-ingredients-into-the-united-states)requires a review within one year to determine whether further action is necessary. Any policy changes could affect Indian exporters, which already face competition and pricing pressure in the US. * **Price controls & Chinese dependence:** Not all medicine prices can be increased freely. India's National Pharmaceutical Pricing Authority regulates the prices of essential medicines, which can limit companies' ability to pass rising costs on to customers. As of July 2026, [**935 formulations were subject to ceiling prices**](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2290387&lang=1®=48). India also remains heavily dependent on China for pharmaceutical raw materials. According to [**government data**](https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222528&lang=1®=3), China accounted for about 74 percent of India's imports of specified APIs, bulk drugs and drug intermediates in FY25\. Any supply disruption could increase costs and affect production. ## How much pharma should your portfolio hold? Sectoral funds work best at 5 to 15 percent of total equity. For most investors, 5 to 10 percent through one or two well managed healthcare funds provides enough exposure without overcommitting to a single theme. Prefer funds with a broader healthcare mandate over pure pharma plays, schemes holding hospitals, diagnostics and medical devices alongside pharma companies offer better diversification within the sector. A SIP of INR 3,000 to INR 5,000 per month alongside a diversified core portfolio is a reasonable starting point. ## The bottom line The Indian pharmaceutical industry has several promising growth drivers, from upcoming drug patent expiries and generic medicines to rising domestic demand and global manufacturing opportunities. These developments could support the sector over the long term. However, the strong surge in pharma stocks in 2026 has also pushed valuations above historical averages. So if you are planning to enter at current levels, you should be careful about chasing recent returns. If you already hold pharma funds, review your portfolio allocation before deciding to book profits. If you are considering a fresh investment, remember that sectoral funds carry higher concentration risk than diversified equity funds. The opportunity in Indian pharma may still be there, but investing at the right price and maintaining a balanced portfolio are just as important as choosing the right sector. _**Disclaimer: This article is for informational and educational purposes only. It should not be treated as investment advice or a recommendation to buy or sell any mutual fund.**_ --- *Investments in securities markets are subject to market risks. Read all the related documents carefully before investing. This content is for educational purposes only and does not constitute investment advice. Arihant Capital Markets Ltd. is a SEBI-registered stock broker.*